Brightsurf Science News & Current Events

December 07, 2019
Lymphoma patients may have new path to remission, even when CAR T therapy fails
A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

Use of venetoclax in transplant conditioning regimen shows promise in myeloid cancers
For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies.

Ancient worm reveals way to destroy toxic cells in Huntington's disease
Research led by a Monash University scientist has identified a highly conserved mechanism in worms and humans that controls the removal of toxic protein aggregates -- hallmarks of neurodegenerative diseases.

Women, exercise and longevity
Women who can exercise vigorously are at significantly lower risk of dying from heart disease, cancer and other causes.

E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients
The ECOG-ACRIN Cancer Research Group today announced results from extended follow-up of patients in its randomized Phase 3 clinical trial, E1912.

Genomic features of AML in patients over age 60 can predict success of stem cell transplant
For older patients with AML, the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute will report at the ASH Annual Meeting.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.